New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

February 2017

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017

Press Releases / By

CRANBURY, N.J., Feb. 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2016.  Recent Highlights Rekynda (bremelanotide) – Under development for Hypoactive Sexual Desire …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017 Read More »

Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™

Press Releases / By

Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs Teleconference and Webcast to be held on February 9, 2017 Feb 03, 2017, 06:00 ET CRANBURY, N.J., Feb. 3, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: …

Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™ Read More »

Scroll to Top